Efficacy and safety of adalimumab (humira) in patients with peripheral spondyloarthritis without ankylosing spondylitis or psoriatic artritis.

Trial Profile

Efficacy and safety of adalimumab (humira) in patients with peripheral spondyloarthritis without ankylosing spondylitis or psoriatic artritis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2015

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Spondylarthritis
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms TIPES
  • Most Recent Events

    • 05 Aug 2015 Results of ABILITY-2 and TIPES study published in the Annals of the Rheumatic Diseases.
    • 11 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 11 Nov 2012 Primary endpoint 'Patient-Global-Assessment' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top